Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ixabepilone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,494,337Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Data from Allarity's PII Trial of IXEMPRA Indicate Potential for Benefit in DRP
    Data from Allarity's PII Trial of IXEMPRA Indicate Potential for Benefit in DRP

    05 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/05/2699631/0/en/Initial-Data-from-Allarity-s-Phase-2-Trial-of-IXEMPRA-Indicate-Potential-for-Improved-Clinical-Benefit-in-DRP-Selected-Metastatic-Breast-Cancer-Patients.html

    GLOBENEWSWIRE
    05 Jul 2023
    Share Share
    Oncology Venture advancing towards next milestone clinical Dev of IXEMPRA®.
    Oncology Venture advancing towards next milestone clinical Dev of IXEMPRA®.

    13 Nov 2019

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2019/11/13/1946075/0/en/Oncology-Venture-advancing-towards-next-milestone-in-its-clinical-development-of-IXEMPRA.html

    GLOBENEWSWIRE
    13 Nov 2019
    Share Share
    Copycats wanted: Pfizer, AZ and more under threat as China solicits generics
    Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

    21 Jun 2019

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/pharma-asia/foreign-drugmakers-under-threat-as-china-rolls-out-drug-list-to-boost-generic

    Angus Liu FIERCE PHARMA
    21 Jun 2019
    Share Share